This 1050-page report, an essential tool for making the most successful strategic decisions, is based on in-depth interviews with 52 HTS directors at pharmaceutical companies, academic centers, and government institutes worldwide as well as 33 key executives from suppliers of HTS products and services.
The report includes
trends in cell-based and biochemical assays, targets and target
classes, role of primary/stem cells, secondary screening,
lead optimization, and early in vitro ADME-Tox, high
content screening (HCS), throughput and compounds, assays
for drug discovery, microplates, detection and label-free
technologies, multiplexing, budgets and spending, organization,
successes of HTS, and unmet needs and opportunities.
| |
